39811-03-5

Usage

InChI:InChI=1/C8H5Cl3N2/c9-3-8-12-6-1-4(10)5(11)2-7(6)13-8/h1-2H,3H2,(H,12,13)

Upstream product

• 6478-80-4 5,6-dichloro-2-hydroxymethyl-1H-benzimidazole 
• 5348-42-5 4,5-Dichloro-1,2-phenylenediamine 
• 79-11-8 chloroacetic acid 
• 79-04-9 chloroacetyl chloride 
• 6306-39-4 1,2-dichloro-4,5-dinitrobenzene 

Downstream Products

• 1036383-52-4 4-(5,6-dichloro-1H-benzoimidazol-2-ylmethoxy)-2-fluoro-5-methoxy-benzaldehyde 

Relevant academic research and scientific papers

PYRAZOLOTRIAZINES

The present invention provides compounds of general formula (I), in which X, R1, R2 and R3 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of hyperproliferative disorders such as cancer disorders, as a sole agent or in combination with other active ingredients.

Synthesis, state-of-the-art NMR-binding and molecular modeling study of new benzimidazole core derivatives as Pin1 inhibitors: Targeting breast cancer

New series of benzimidazole ring core conjugated with either dithiocarbamate or thiopropyl linkers, hybridized with different secondary amines were synthesized; 5–15 and 22–31; respectively. The new compounds were characterized by different spectroscopic techniques (1H, 13C 1D & 2D NMR, ESI-MS and IR). They were screened for in vitro anticancer activity against breast cancer using MCF7 cell line. The results obtained revealed that compounds 5, 12, 15 and 25 were the most active among the synthesized series exhibiting IC50 15N-labeled Pin1 enzyme was conducted using state-of-the-art 2D NMR binding experiments. Results showed promising binding between compounds 5, 12, and 25 by chemical shift perturbation (peak shifting or peak disappearance). Molecular docking study were quite valuable to explain the binding mode of active derivatives via hydrogen bonding. Additional contact preferences and surface mapping studies stated the similarity pattern between active candidates which may pave the way for more precise anti breast cancer target optimization.

2-Substituted benzimidazole piperidines analogs as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders

The present invention discloses compounds of formula I wherein Ar, Y, m, n, R1 and R4 are herein defined, said compounds being novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.

Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity

The present invention discloses compounds which, are novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.

Benzimidazoles and isosteric compounds as potent and selective factor Xa inhibitors.

Benzimidazoles and their isosteric compounds as factor Xa inhibitors are discussed.

2-(4-pyridylaminomethyl)-benzimidazole derivatives having antiviral activity

Provided herein is an antiviral 2-(4-pyridylaminomethyl)-benzimidazole of the formula: STR1 wherein R is a radical selected from the groups consisting of hydrogen, short-chain alkyl, short-chain alkoxy, benzoyl, halogenomethyl, halogen, nitro and amino groups; the preparation of these compounds and antiviral composition containing such compounds.